AVAGE Drug Patent Profile
✉ Email this page to a colleague
When do Avage patents expire, and what generic alternatives are available?
Avage is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in AVAGE is tazarotene. There are eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tazarotene profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Avage
A generic version of AVAGE was approved as tazarotene by TARO on April 3rd, 2017.
Summary for AVAGE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 129 |
Patent Applications: | 4,415 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for AVAGE |
DailyMed Link: | AVAGE at DailyMed |
US Patents and Regulatory Information for AVAGE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | AVAGE | tazarotene | CREAM;TOPICAL | 021184-003 | Sep 30, 2002 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AVAGE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan | AVAGE | tazarotene | CREAM;TOPICAL | 021184-003 | Sep 30, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AVAGE
See the table below for patents covering AVAGE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Greece | 3005243 | ⤷ Try a Trial | |
South Africa | 8801515 | ⤷ Try a Trial | |
Australia | 1326888 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AVAGE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0284288 | 12/1998 | Austria | ⤷ Try a Trial | PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203 |
0284288 | SPC/GB98/002 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730 |
0031058 | 98C0008 | Belgium | ⤷ Try a Trial | PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |